Free tool
FAERS Monitor: Egrifta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022505 or its brand name (Egrifta, Tesamorelin Acetate). Reports on generic versions are filed under their own applications.
Reports
1,692
Serious
345
20% of reports
Hospitalization
132
Death reported
32
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue297
- incorrect dose administered164
- injection site pain160
- drug ineffective130
- product preparation issue122
- arthralgia113
- injection site bruising99
- weight increased99
- therapeutic product effect incomplete86
- injection site pruritus83
- wrong technique in product usage process79
- pain in extremity75
- fatigue65
- peripheral swelling62
- pruritus54
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 143 |
| 2021 | 171 |
| 2022 | 203 |
| 2023 | 348 |
| 2024 | 341 |
| 2025 | 233 |
| 2026 | 249 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,467 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product preparation issueSignal | 122 | 235.6 | 198.2 | 27,745 |
| injection site bruisingSignal | 99 | 15.4 | 12.8 | 1,326 |
| injection site pruritusSignal | 83 | 15.4 | 12.5 | 1,107 |
| therapeutic product effect incompleteSignal | 86 | 15.0 | 12.2 | 1,116 |
| product dose omission issueSignal | 297 | 12.6 | 11.3 | 3,192 |
| incorrect dose administeredSignal | 164 | 8.9 | 7.7 | 1,160 |
| injection site painSignal | 160 | 6.5 | 5.6 | 748 |
| weight increasedSignal | 99 | 5.5 | 4.5 | 363 |
| peripheral swellingSignal | 62 | 5.0 | 3.9 | 196 |
| wrong technique in product usage processSignal | 79 | 4.8 | 3.9 | 240 |
| arthralgiaSignal | 113 | 3.4 | 2.8 | 191 |
| pain in extremitySignal | 75 | 3.2 | 2.5 | 110 |
| pruritus | 54 | 1.7 | 1.3 | 17 |
| drug ineffective | 130 | 1.2 | 1.0 | 6 |
| fatigue | 65 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.